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ABSTRACT 
 
Alterations in neurochemical metabolites are thought to play a role in the pathophysiology of 
psychosis onset. Oxytocin, a neuropeptide with prosocial and anxiolytic properties, 
modulates glutamate neurotransmission in preclinical models but its neurochemical effects 
in people at high risk for psychosis are unknown. We used proton magnetic resonance 
spectroscopy (1H-MRS) to examine the effects of intranasal oxytocin on glutamate and other 
metabolites in people at Clinical High Risk for Psychosis (CHR-P) in a double-blind, placebo-
controlled, crossover design. 30 CHR-P males were studied on two occasions, once after 
40IU intranasal oxytocin and once after placebo. The effects of oxytocin on the 
concentration of glutamate, glutamate+glutamine and other metabolites (choline, N-
acetylaspartate, myo-inositol) scaled to creatine were examined in the left thalamus, anterior 
cingulate cortex (ACC) and left hippocampus, starting approximately 75, 84 and 93 minutes 
post-dosing, respectively. Relative to placebo, administration of oxytocin was associated 
with an increase in choline levels in the ACC (p=.008, Cohen’s d =0.54). There were no 
other significant effects on metabolite concentrations (all p>.05). Our findings suggest that, 
at ~75-93 minutes post-dosing, a single dose of intranasal oxytocin does not alter levels of 
neurochemical metabolites in the thalamus, ACC, or hippocampus in those at CHR-P, aside 
from potential effects on choline in the ACC.  
 
Keywords: glutamate, oxytocin, magnetic resonance spectroscopy, psychosis risk, 
schizophrenia, neuroimaging 
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INTRODUCTION  
 
The onset of psychosis is usually preceded by attenuated psychotic symptoms (Fusar-Poli et 
al, 2016b) and a clinical presentation that can include social, cognitive and functional 
impairment (Fusar-Poli et al, 2012a, 2013a, 2015). Such individuals are said to be at Clinical 
High-Risk for Psychosis (CHR-P)(Fusar-Poli, 2017) and have approximately 20% risk of 
developing a first-episode psychosis over the following two years (Fusar-Poli et al, 2016a). 
The neurobiological mechanisms underlying psychosis onset remain incompletely 
understood, but alterations in regional brain structure, function and neurochemical 
composition have been observed in CHR-P samples (Allen et al, 2016; Bartholomeusz et al, 
2017; Fusar-Poli et al, 2012b; Modinos et al, 2018a). 
 
In particular, accumulating evidence suggests that the pathophysiological processes 
underlying psychosis onset may be driven by dysregulated glutamate neurotransmission 
(Lieberman et al, 2018), with hypofunction of N-methyl-D-aspartate receptors (NMDAR) on !-aminobutyric acid (GABA)-ergic interneurons leading to disinhibition of pyramidal cells, 
and via polysynaptic projection pathways from the hippocampus to the midbrain/striatum, to 
midbrain hyperdopaminergia (Figure 1) (Lisman et al, 2008; Modinos et al, 2015). Glutamate 
is an ubiquitous neurotransmitter with excitotoxic potential (Farber et al, 1995), and animal 
models have demonstrated that excess extracellular glutamate is sufficient to induce 
hippocampal hypermetabolism and volume loss (Lieberman et al, 2018; Schobel et al, 2013) 
comparable to that observed as the CHR-P state progresses to psychosis (Allen et al, 2016; 
Ho et al, 2017; Schobel et al, 2013). Novel pharmacotherapies that can modulate the 
glutamate system—or associated neural circuits—have therefore become a target for drug 
development (Lieberman et al, 2018; Millan et al, 2016). 
 
<Figure 1> 
 
In humans, metabolite levels can be quantified in vivo using proton magnetic resonance 
spectroscopy (1H-MRS)(Provencher, 1993). Using this technique, numerous (but not all 
(Merritt et al, 2016)) studies have reported alterations in glutamate (and/or glutamate plus 
glutamine (Glx)) levels in people at high risk of psychosis vs controls, particularly in the 
hippocampus (Bloemen et al, 2011; Shakory et al, 2018), frontal (Merritt et al, 2016) or 
anterior cingulate cortex (ACC)(Stone et al, 2009; Tibbo et al, 2004) and thalamus (Stone et 
al, 2009). Moreover, within CHR-P samples, altered metabolite levels at baseline appear 
related to clinical outcomes; thalamic glutamate is lower at baseline in those who do not 
remit by follow up (Egerton et al, 2014), and baseline hippocampal glutamate is elevated in 
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those who transition (vs those who do not), and in those with poor (vs good) functional 
outcomes (Bossong et al, 2018). There is also evidence that neurochemical alterations in 
CHR-P are not restricted to glutamate or Glx; higher levels of hippocampal myo-inositol at 
first presentation have been reported in CHR-P patients with poor functional and clinical 
outcomes (with effect sizes surpassing that of glutamate), which suggests that hippocampal 
integrity may be compromised more generally (Bossong et al, 2018). Metabolite alterations 
have also been observed in other brain regions in CHR-P and other (i.e. familial) high-risk 
groups, such as reduced N-acetylaspartate in the thalamus (Stone et al, 2009; Tandon et al, 
2013; Yoo et al, 2009), ACC (Capizzano et al, 2011; Jessen et al, 2006), and caudate 
(Keshavan et al, 2009)—although increases are also observed in the caudate (de la Fuente-
Sandoval et al, 2011). Increased Glx has been reported in the thalamus and caudate, as 
well as increased (de la Fuente-Sandoval et al, 2016) or decreased (Menschikov et al, 2016) 
medial prefrontal GABA—although differences are not always found (Modinos et al, 2018b; 
Wang et al, 2016). Finally, other studies have reported increased choline in the ACC 
(Tandon et al, 2013), prefrontal cortex (Wood et al, 2003) and hippocampus (Capizzano et 
al, 2011) in populations at risk for psychosis. 
 
Prevention of psychosis in patients at CHR-P and amelioration of symptoms are clinical 
priorities. However, there are currently no licensed pharmacological treatments for this 
patient group, which remains an unmet clinical need (Davies et al, 2018a, 2018b). One 
potential novel treatment is the neuropeptide oxytocin, which is currently under investigation 
in relation to a number of neuropsychiatric disorders characterised by social dysfunction, 
such as autism spectrum disorder and schizophrenia. Oxytocin is a key modulator of social 
and emotional processes and possesses anxiolytic, prosocial, and potential anticonvulsant 
properties (Domes et al, 2007; Guastella et al, 2008; Kanat et al, 2015; Kirsch, 2005; Meyer-
Lindenberg et al, 2011). Intranasal oxytocin is also safe and has a benign side effect profile 
(MacDonald et al, 2011), which is particularly important in CHR-P groups because many will 
not go on to develop psychosis. The effects of oxytocin on brain metabolites are not 
completely clear, but available evidence implicates some of the metabolites that have been 
found to be abnormal in CHR-P individuals: glutamate, Glx, N-acetylaspartate, choline and 
GABA. Specifically, in a previous randomised, double-blind, placebo-controlled crossover 
trial of a single acute dose of 24IU intranasal oxytocin in people with autism spectrum 
disorder, oxytocin’s normalisation of brain activation during a social cognition task and 
improvement in social-communication symptoms was found to be directly related to its 
effects on N-acetylaspartate levels (Aoki et al, 2015). Choline levels in the ACC also 
appeared to be decreased by oxytocin, albeit at a relaxed significance threshold (p=.02, 
uncorrected for multiple comparisons; see supplementary material in (Aoki et al, 2015)). In a 
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separate randomised, double-blind, placebo-controlled, crossover trial of 48IU/day oxytocin, 
which was administered repeatedly over 6 weeks in people with autism spectrum disorder, 
oxytocin significantly reduced levels of Glx and N-acetylaspartate in the medial prefrontal 
cortex/ACC relative to placebo (Benner et al, 2018). This prior work demonstrates that 
exogenously administered oxytocin can alter levels of metabolites as measured by 1H-MRS. 
Evidence for effects of oxytocin on glutamate and GABA comes from preclinical studies. For 
instance, oxytocin dose-dependently restores social and sensorimotor gating deficits in 
NMDAR antagonist-treated rats (Feifel and Reza, 1999; Lee et al, 2005). Mice lacking the 
oxytocin receptor (through gene knock-out) are more vulnerable to NMDAR antagonist-
induced sensorimotor gating deficits (but not those induced by amphetamine or 
apomorphine), which suggests that it is the glutamatergic (rather than dopaminergic) 
component of sensorimotor gating that is protected by oxytocin (Caldwell et al, 2009). In 
mice, oxytocin attenuates methamphetamine-induced changes in glutamatergic 
neurotransmission in prefrontal cortex and hippocampus via regulation of NMDAR subunit 
(NR1) and glutamate transporter (GLT1) expression (Qi et al, 2012). Furthermore, in 
animals, oxytocin has been found to enhance the signal-to-noise ratio of pyramidal cell firing 
by targeting fast-spiking GABAergic interneuron function (Owen et al, 2013; Zaninetti and 
Raggenbass, 2000)—part of the neural circuit implicated in psychosis onset (Lieberman et 
al, 2018; Lisman et al, 2008; Modinos et al, 2015). When this circuit is acutely manipulated 
in humans, for example, by inducing NMDAR hypofunction using NMDAR antagonists, or by 
reducing glutamate release itself (e.g. using n-acetyl-cysteine), increases and decreases 
(respectively) in the concentrations of regional glutamate/Glx levels as measured by 1H-
MRS can be observed (Kegeles et al, 2014; Kraguljac et al, 2017; McQueen et al, 2018; 
Schmaal et al, 2012). This demonstrates that the acute modulation of microcircuit function 
can alter metabolite concentrations, and that this can be observed experimentally using 1H-
MRS. 
 
Despite these initial findings, no studies have yet examined the effects of intranasal oxytocin 
on neurochemical metabolites in CHR-P individuals, which would further our understanding 
of its neurophysiological mechanism of action and potential disease-engaging effects. To fill 
this gap in knowledge, we investigated the effects of intranasal oxytocin on several 
neurochemical metabolites that are thought to be altered in CHR-P individuals in a 
randomised, double-blind, oxytocin vs placebo single-dose challenge 1H-MRS study. In line 
with previous findings in CHR-P individuals, our primary aim was to assess the effects of 
oxytocin on levels of glutamate, and glutamate plus glutamine (Glx), in the left hippocampus, 
ACC and left thalamus (Bloemen et al, 2011; Shakory et al, 2018; Stone et al, 2009; Tibbo et 
al, 2004). In view of recent literature suggesting that N-acetylaspartate, myo-inositol and 
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choline may be altered in populations at risk of psychosis (Bossong et al, 2018; Tandon et 
al, 2013), and that oxytocin’s effects may involve several neurochemical pathways (Aoki et 
al, 2015; Benner et al, 2018; Ninan, 2011; Qi et al, 2012), our secondary aim was to 
examine the effects of oxytocin on these metabolite levels. 
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EXPERIMENTAL PROCEDURES 
 
Participants 
The study received National Research Ethics Service approval (14/LO/1692) and all 
subjects gave written informed consent. Using data from a previous 1H-MRS study (Stone et 
al, 2009) we conducted a power calculation using G*Power 3, which indicated that a sample 
size of 30 was sufficient to detect a medium within-subject effect size (dz=0.53), when alpha 
= 0.05 and power = 80%. Accordingly, thirty male, help-seeking CHR-P individuals aged 18-
35 were recruited from two specialist early detection services—the Outreach and Support in 
South London (OASIS) (Fusar-Poli et al, 2013b) and Tower Hamlets Early Detection Service 
(THEDS). A CHR-P status was determined using the Comprehensive Assessment of At-Risk 
Mental States (CAARMS) 12/2006 criteria (Yung et al, 2005). The CHR-P state is 
heterogeneous (Fusar-Poli et al, 2016a) because subjects can meet one or more of the 
following subgroup criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent 
psychotic symptoms (BLIPS, psychotic episode lasting <1 week, remitting without 
treatment), or (c) either schizotypal personality disorder or first-degree relative with 
psychosis (Yung et al, 2005), all coupled with functional decline. Individuals were excluded if 
there was a history of previous psychotic disorder (with the exception of BLIPS, some of 
whom may meet Acute and Transient Psychotic Disorder criteria (Fusar-Poli et al, 2017)) or 
manic episode, exposure to antipsychotics, neurological disorder or current substance-use 
disorder, estimated IQ <70, acute intoxication on the day of scanning, and any 
contraindications to magnetic resonance imaging (MRI) or intranasal oxytocin or placebo. 
 
Procedure 
We used a randomised, double-blind, 40IU intranasal oxytocin vs placebo single-dose 
challenge in a crossover design (one-week wash out). During each challenge, subjects 
underwent an MRI scan which started at 11:30AM to minimise potential effects of diurnal 
variation in oxytocin or vasopressin (Paloyelis et al, 2016). Prior to the first scan, subjects 
completed a computerised Reading the Mind in the Eyes (RMET) task (Baron-Cohen et al, 
2001), which indexes mentalising (theory of mind) ability, for use in correlation analyses. The 
RMET requires participants to match the mental state of a person (as shown in a photograph 
of the eye region only) with one of four possible mental state words. Higher scores (out of a 
maximum of 36) index better mentalising ability. For descriptive purposes, we also collected 
information on baseline anxiety (State-Trait Anxiety Inventory [STAI]), medication history, 
use of alcohol (Alcohol Use Disorders Identification Test [AUDIT]), tobacco and cannabis, 
and functioning using the Global Functioning (GF) Role and Social scales (Cornblatt et al, 
2007). Intranasal administration followed recommended guidelines and a protocol adopted 
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by a previous study conducted at our institute (Paloyelis et al, 2016). Briefly, participants 
self-administered one puff (4IU) of intranasal oxytocin or matched placebo every 30 
seconds, alternating between nostrils, until 40IU had been administered (Supplementary 
Material). Although not presented here, the MRI scan included arterial spin labelling, a 
functional MRI (fMRI) task, various structural scans and resting state fMRI, followed by the 
three 1H-MRS sequences (detailed below). 
 
Magnetic Resonance Imaging 
All scans were conducted on a General Electric Discovery MR750 3 Tesla system (General 
Electric, Chicago, USA) using a 32-channel head coil. A three-dimensional sagittal high-
spatial-resolution Inversion Recovery Spoiled Gradient Echo (IR-SPGR) T1-weighted scan 
(TE=3.016ms; TR=7.31ms; TI=400ms; voxel size=1.1x1.1x1.2mm3) was acquired for voxel 
planning and calculation of 1H-MRS voxel tissue content. 1H-MRS spectra were acquired in 
the left hippocampus, ACC, and left thalamus (Figure 2) using conventional Point-Resolved 
Spectroscopy acquisition (PRESS; TR = 3000ms; TE = 30ms; 96 averages) in three 
separate 6-minute scans. We employed the standard GE PROBE (Proton Brain 
Examination) sequence, which uses a standardised chemically selective suppression 
(CHESS) water suppression routine. Unsuppressed water reference spectra (16 averages) 
were also acquired as part of the standard acquisition for subsequent eddy current 
correction and water scaling. Shimming was optimised, with auto-prescan performed twice 
before each scan. The structural T1-weighted scan was used to plan the voxel placement as 
per standardised protocols, with voxel sizes of (right-left, anterior-posterior, superior-inferior) 
20x20x15mm3 in the hippocampus, 20x20x20mm3 in the ACC, and 15x20x20mm3 in the 
thalamus. The mean ± SD of the time from dosing offset (end of intranasal administration) 
for each region was: thalamus (75 ± 4 mins), ACC (84 ± 5 mins), and hippocampus (93 ± 6 
mins). These equate to approximate (mean) post-dosing sampling periods of: thalamus (75-
81 mins), ACC (84-90 mins), and hippocampus (93-99 mins). 
 
Data Processing 
Spectra were analysed using LCModel (Provencher, 1993) version 6.3-1L using the 
standard basis set of 16 metabolites (L-alanine, aspartate, creatine, phosphocreatine, 
GABA, glucose, glutamine, glutamate, glycerophosphocholine, glycine, myo-inositol, L-
lactate, N-acetylaspartate, N-acetylaspartylglutamate, phosphocholine, and taurine) 
acquired at the same field strength (3 Tesla), localisation sequence (PRESS), and echo time 
(30 ms). Model metabolites and concentrations used in the basis set are fully detailed in the 
LCModel manual (http://s-provencher.com/pub/LCModel/manual/manual.pdf). Poorly fitted 
metabolite peaks (Cramer-Rao minimum variance bounds [CRLB] of >20% as reported by 
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LCModel) were excluded from further analysis. Spectral quality was further assessed using 
signal-to-noise ratio (SNR) and spectral linewidths (full width at half-maximum; FWHM). 
 
Our primary analysis used metabolite levels scaled to creatine. However, because creatine 
may be influenced by the experimental condition (oxytocin vs placebo), we also report water-
scaled metabolite levels corrected for voxel tissue content. To calculate and correct for 1H-
MRS voxel tissue content, an in-house script was used to (a) segment the T1-weighted 
structural images into grey matter, white matter, and cerebrospinal fluid (CSF) using 
Statistical Parametric Mapping 12 (SPM12; Wellcome Trust Centre for Neuroimaging, 
London, UK) running in Matlab R2017a, (b) locate and map the coordinates of each voxel to 
the segmented T1 images, and (c) provide the tissue content proportions. Metabolite values 
were corrected for voxel tissue content using the formula: Mcorr= M×([GM×1.21] +WM+ 
[CSF×1.55]) / (WM+GM), where M is the uncorrected metabolite value and GM/WM/CSF are 
proportions of grey matter, white matter and CSF, respectively. The formula assumes a CSF 
water concentration of 55,556 mol/m3 and the LCModel default brain water concentration of 
35,880 mol/m3 (Gasparovic et al, 2006; Kreis et al, 1993). Apart from assuming T2 = 80 ms 
for tissue water, no corrections were applied for metabolite and water relaxation times. 
 
Statistical Analysis 
Statistical analyses were performed in SPSS version 24 (IBM Corp., Armonk, NY). Paired t-
tests were used to examine differences in data quality (i.e. in linewidths, signal-to-noise 
ratio, CRLB, and voxel tissue proportions) between conditions. The effects of oxytocin vs 
placebo on regional brain 1H-MRS metabolite levels were assessed using paired t-tests. Our 
primary hypothesis tested for effects on glutamate and Glx scaled to creatine, and our 
secondary hypothesis tested for effects on other metabolites (myo-inositol, N-
acetylaspartate and choline) scaled to creatine. Choline (or “total choline”) was the sum of 
glycerophosphocholine and phosphocholine. The alpha level was Bonferroni corrected 
(thresholded p<.05 / 5 metabolites= p<.01, two-tailed) for multiple comparisons per region. 
For both primary and secondary analyses, boxplots were used to identify potential outliers 
and paired t-tests were repeated after their exclusion in sensitivity analyses. We also 
repeated the primary and secondary analyses after excluding those participants taking 
antidepressants (N=8) or benzodiazepines (N=1). The same procedures as detailed above 
were used in the analysis of water-scaled metabolite levels corrected for voxel tissue content 
(which also included analysis of creatine itself), which we conducted to ensure that our 
results were not driven by the scaling to creatine. Exploratory Spearman’s correlations were 
then used to examine whether the effects of oxytocin on the primary outcome (change in 
glutamate and Glx levels—scaled to creatine—in the hippocampus, ACC and thalamus in 
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the oxytocin vs placebo condition) were predicted by the baseline level of behavioural 
measures that characterise CHR-P patients. These included attenuated positive psychotic 
symptoms (sum of severity scores for items P1-P4 of the CAARMS) and social cognition, 
measured through the Reading the Mind in the Eyes task (RMET) scores. Since these 
correlations were exploratory in nature they were not corrected for multiple comparisons. 
Finally, given some attrition in study participation, we updated our power calculation for the 
primary hypotheses (glutamate and Glx) to assess the actual power of our analyses (see 
Supplementary Material).
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RESULTS 
 
Sample Characteristics 
Demographic and clinical characteristics of the sample are presented in Table 1. One 
subject was removed due to protocol violations, and one further subject did not complete the 
scanning session due to experiencing attenuated psychotic symptoms (at ~75mins during 
the placebo condition), leaving a sample of N=28 for the ACC and thalamus. Two further 
subjects did not complete the hippocampal 1H-MRS scan, leaving N=26 for this region. No 
adverse side effects of oxytocin were clinically observed.  
 
<Table 1> 
<Figure 2> 
 
1H-MRS data quality 
Representative spectra for all regions (left hippocampus, ACC, and left thalamus) are 
provided in Figure 2. Spectra were of good quality in all regions—no data were excluded due 
to Cramer-Rao minimum variance bounds >20% and no significant differences in spectral 
quality or voxel tissue content were observed between oxytocin and placebo conditions 
(Table 2). 
 
<Table 2> 
 
Effects of oxytocin on glutamate and Glx levels 
The analysis of the primary outcome revealed no significant effects of oxytocin vs placebo 
on glutamate or Glx scaled to creatine (nor in voxel tissue-corrected glutamate or Glx levels) 
in the hippocampus, ACC or thalamus (Table 3).  
 
Effects of oxytocin on other metabolite levels  
Analysis of the secondary outcomes revealed no significant effects on any other metabolites 
quantifiable from the 1H-MRS spectra (myo-inositol, choline and N-acetylaspartate) in any 
region, with the exception of choline scaled to creatine in the ACC, which was significantly 
increased in the oxytocin (mean ± SD; 0.25 ± 0.02) relative to the placebo (mean ± SD; 0.24 
± 0.02) condition (t(27)=2.88, p=.008; Cohen’s d =0.54; Figure 3)(Table 3). When using ACC 
choline levels corrected for voxel tissue content, we observed a numerical increase in the 
oxytocin (mean ± SD; 2.93 ± 0.36) relative to the placebo (mean ± SD; 2.77 ± 0.41) condition 
(t(27)=2.57, p=.02; Table 3), but this effect was not significant at the Bonferroni-corrected 
significance threshold of p<.01 (Table 3). 
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<Table 3> 
<Figure 3> 
 
Sensitivity analysis 
Removal of outliers made no material change to the results of any statistical test (Table 3). 
Removal of subjects taking antidepressants and benzodiazepines meant that choline scaled 
to creatine was now significantly increased in the thalamus in the oxytocin (mean ± SD; 0.30 
± 0.03) relative to the placebo (mean ± SD; 0.28 ± 0.03) condition (t(20)=3.11, p=.006). 
 
Exploratory correlations 
Social Cognition 
One subject did not complete the Reading the Mind in the Eyes task (RMET), leaving N=25 
for the hippocampus, and N=27 for the ACC and thalamus. RMET (theory of mind) scores 
were negatively associated with absolute change in glutamate scaled to creatine (rho= -.546, 
p=.005) and Glx scaled to creatine (rho= -.509, p=.009) in the hippocampus (Supplementary 
Table S1). That is, those with better theory of mind scores tended to have the biggest 
decreases in hippocampal glutamate after oxytocin, while those with lower scores (where 
oxytocin is presumed to have the greatest effect (Feeser et al, 2015; Spengler et al, 2017)) 
tended to have an increase in hippocampal glutamate after oxytocin (Supplementary Figure 
S1). There were no significant correlations between RMET scores and glutamate or Glx 
levels in the ACC or thalamus (all p>.05; Table S1). It should be noted that exploratory 
correlations were not corrected for multiple comparisons. 
 
Attenuated Psychotic Symptoms 
One subject had one item missing out of the four items that constitute the positive subscale 
of the CAARMS, leaving N=25 for the hippocampus, N=27 for the ACC and N=27 for the 
thalamus. There were no significant correlations between CAARMS attenuated psychotic 
symptom scores and change in glutamate or Glx scaled to creatine in the hippocampus, 
ACC or thalamus (Supplementary Table S2). 
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DISCUSSION 
 
This is the first study to investigate the neurochemical effects of a single dose of oxytocin in 
CHR-P individuals. The key finding was that oxytocin did not modulate glutamate (or 
glutamate plus glutamine; Glx) levels in the hippocampus, ACC or thalamus in the time 
interval examined (approximately 75-93 minutes post-dosing). There were also no effects on 
other metabolites, with the exception of choline in the ACC, concentrations of which were 
significantly increased after oxytocin. 
 
Our primary hypothesis, that an acute dose of oxytocin would modulate glutamate or Glx 
levels in CHR-P individuals, was not verified. One implication of these findings relates to the 
potential mechanism of oxytocin’s effects. A previous study found that an acute dose of 
intranasal oxytocin had marked effects on cerebral perfusion (Paloyelis et al, 2016) across 
regions that show neurochemical alterations in CHR-P groups (Merritt et al, 2016; Poels et 
al, 2014; Tandon et al, 2013). Our own work has also revealed that acute oxytocin 
modulates hippocampal perfusion in those at CHR-P (Davies et al, 2019). Given these 
demonstrable neural effects, in this study we sought to test the hypothesis that oxytocin also 
modulates metabolite concentrations (especially glutamate and Glx) in CHR-P individuals. 
Negative findings are underreported in the scientific literature and can be difficult to interpret, 
but three different possibilities are presented below. First, while we did not find any effect on 
glutamate or Glx levels in the hippocampus, ACC or thalamus, it is still possible that oxytocin 
mediates its effects via modulation of glutamatergic neurotransmission either (a) directly, but 
we are not able to detect it using 1H-MRS (e.g. due to its lack of specificity for neuronal 
glutamate/Glx and large voxel size), or (b) indirectly via modulation of GABA and associated 
neural microcircuits, which was not directly quantifiable in the current study. Indeed, some 
preclinical studies have shown that exogenous oxytocin administration does not alter basal 
glutamate levels per se, but blocks or attenuates changes in glutamate induced by 
deleterious manipulations such as drug-induced deficits and restraint stress (Qi et al, 2009, 
2012)—while it can directly alter basal GABA levels (Qi et al, 2012). It may also be the case 
that the heterogeneity inherent in CHR-P samples, both clinically and in relation to regional 
metabolite concentrations at the specific time of scanning (which may differ between those 
who will and will not later transition, and those with good vs poor functional outcomes 
(Bossong et al, 2018)), may dilute and obscure observable oxytocin effects on glutamate 
when measured at group level. Stratification of CHR-P samples in future studies would—in 
theory—allow exploration of this possibility. 
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A second possible explanation for these negative findings may be that the time interval 
between intranasal administration of oxytocin and the onset of the 1H-MRS acquisition was 
too long and potential effects on glutamate/Glx were missed. The mean ± SD of the time 
since intranasal administration for each region in the current study was: thalamus (75 ± 4 
mins), ACC (84 ± 5 mins), and hippocampus (93 ± 6 mins). Early—albeit indirect—evidence 
suggested that the neural effects of intranasal oxytocin would last at least as long as our 
data sampling intervals. For example, notwithstanding the extremely small sample, previous 
work reported that following intranasal administration, the oxytocin signal in cerebrospinal 
fluid only begins to significantly increase at 75 minutes post-dosing (Striepens et al, 2013). 
Another study found that while the effects of oxytocin on human cerebral blood flow peak at 
39-51 minutes post-administration (with a gradual diminution thereafter), they observed 
sustained perfusion effects over the entire post-treatment interval (up to 78 minutes) 
(Paloyelis et al, 2016). However, more recent work suggests that the effects of oxytocin vary 
as a function of method of administration, brain region, dosage and time since dosing 
(Martins et al, under review). For example, in one study of healthy males, oxytocin’s effects 
on amygdala inhibition were observed only between 45-70 minutes post-administration, and 
not before or after (Spengler et al, 2017). A forthcoming study (Martins et al, under review) 
using a double-blind, placebo-controlled, crossover procedure and comparing various 
methods of oxytocin administration, indicates that oxytocin-induced decreases in amygdala 
perfusion are present only within the first 15-30 minutes post-dosing. Furthermore, we 
recently showed that in the same CHR-P sample as used in the current study, the effects of 
oxytocin on hippocampal perfusion were more robust in the earlier (22-28 minutes) vs the 
later (30-36 minutes) post-dosing interval (Davies et al, 2019). It may therefore be that in the 
hippocampus, thalamus and ACC, changes in glutamate and Glx are occurring closer to the 
time of administration. 
 
Third, the observed lack of effects (especially on glutamate and Glx) may be related to the 
acute vs long-term effects of repeated oxytocin administration. A recent study found that 
repeated administration of 48IU/day intranasal oxytocin over 6 weeks in people with autism 
spectrum disorder significantly decreased N-acetylaspartate and Glx levels in the medial 
prefrontal cortex (Benner et al, 2018), effects that were not observed after 24IU acute 
challenge (Aoki et al, 2015). Akin to the current work, both of the aforementioned studies 
were randomised, double-blind, placebo-controlled, crossover designs (Aoki et al, 2015; 
Benner et al, 2018). In addition, their mouse model showed that repeated—but not acute—
oxytocin administration significantly downregulated Nr2b (a subunit of the glutamate NMDA 
receptor) transcript expression, while acute administration reduced levels of molecules 
associated with the oxytocinergic system (oxytocin mRNA) and with neural activity 
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(immediate early genes; cFos and Arc), but not Nr2b (Benner et al, 2018). In light of these 
findings, it is possible that longer-term treatment with oxytocin would have had significant 
effects on the glutamate system, with altered metabolite levels detectable using 1H-MRS. 
 
A final potential contributing factor for our lack of observed effects on glutamate and Glx 
relates to statistical power. The current study had a relatively large sample size for a 
neuroimaging-based, within-subject drug challenge study. However, we cannot rule out the 
possibility that oxytocin had effects of smaller magnitude (e.g. Cohen’s D less than ~0.56), 
which corresponds to a maximum percent change in metabolite levels of between ~13-20% 
(depending on the brain region). 
 
Our secondary hypothesis was that oxytocin would modulate metabolites that have been 
found to be altered in CHR-P and other high-risk groups (Bossong et al, 2018; Stone et al, 
2009; Tandon et al, 2013). We found that, at ~75-93 minutes post-dosing, oxytocin had no 
effects on concentrations of N-acetylaspartate, myo-inositol or creatine in the hippocampus, 
ACC or thalamus. The poor availability of previous literature hinders interpretation of these 
results, and as discussed above, we may have had insufficient power to test for effects on 
these metabolites. We also found that oxytocin had no effect on choline in the hippocampus 
and thalamus, but had significant effects on choline in the ACC, which was significantly 
increased after oxytocin. Choline has a two-fold greater concentration in glial cells compared 
to neurons (Urenjak et al, 1993), is a precursor and metabolite of acetylcholine, and as an 
essential component of membrane phospholipids is considered a marker of membrane 
turnover and integrity (Bertolino and Weinberger, 1999). Previous evidence has implicated 
altered choline in the early phases of psychosis. Increased regional choline levels have been 
found in patients with first-episode psychosis (Plitman et al, 2016) and schizophrenia 
(Bustillo et al, 2014) and is associated with a longer duration of untreated illness (Théberge 
et al, 2004), potentially due to glutamatergic excitotoxicity causing cell damage (Gasull et al, 
2000), resulting in elevated choline from increased cell membrane turnover (Bertolino and 
Weinberger, 1999; Théberge et al, 2004), or potentially due to increased astrocytic turnover 
of glutamatergic compounds (Bustillo et al, 2014; Plitman et al, 2016). There is also specific 
evidence suggesting that abnormal choline levels characterise populations at risk of 
psychosis. Earlier work showed that choline levels are altered in familial high risk individuals 
vs low risk controls in the hippocampus (Capizzano et al, 2011) and in the ACC (Tandon et 
al, 2013), with ACC increases correlating with attenuated psychotic symptom severity and 
schizotypy (Tandon et al, 2013). Within CHR-P individuals, ACC choline levels are increased 
in those who go on to transition vs those who do not (Jessen et al, 2006)—although CHR-P 
differences are not always found (Stone et al, 2009; Uhl et al, 2011). There is also evidence 
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demonstrating an effect of oxytocin on choline in the ACC. A previous study conducted in 
males with autism spectrum disorder found that acute administration of oxytocin modulated 
levels of choline—but not any other metabolite—in the medial prefrontal cortex/ACC, albeit 
at a relaxed statistical theshold (Aoki et al, 2015). However, it is important to note that the 
oxytocin effects on choline were not within our primary hypothesis and therefore these 
findings should be interpreted with caution. Despite similar results in other 
neurodevelopmental disorders (Aoki et al, 2015), further independent replication studies are 
needed to validate this finding. The stringent correction for multiple comparisons 
(implemented because our primary hypothesis was for glutamate and Glx only) may also 
account for the (statistically) discordant choline results from the creatine-scaled vs the voxel 
tissue content-corrected methods. 
 
This study has some limitations. First, 1H-MRS is not able to distinguish between intracellular 
vs extracellular (or neuronal vs non-neuronal) metabolites, and rather represents a whole 
tissue measure within the specified voxel (Jelen et al, 2018). This leaves the possibility that 
oxytocin modulated glutamate/Glx specifically in the neuronal component (i.e. related to 
neurotransmission/pyramidal neurons—which represents a very small proportion of the total 
glutamate in brain tissue—in the region of uM concentrations) vs the non-neuronal 
component (i.e. within glia), which cannot be discriminated. Nevertheless, 1H-MRS at 3 
Tesla is widely used to quantify glutamate and Glx and the data acquired in the current study 
were of high quality. We therefore think it unlikely that acute oxytocin has effects on 
neurochemical metabolite concentrations other than choline in CHR-P individuals (at least at 
~75-93 minutes post-dosing) and propose that this absence of effects is not attributable to 
methodological shortcomings. Scanning at higher field strengths (e.g. 7 Tesla) and 
advanced techniques (such as GluCEST or 1H-fMRS) are now becoming available, and will 
enable future research to reliably separate spectral components and investigate dynamic 
changes in metabolite levels (Jelen et al, 2018; Roalf et al, 2017; Thakkar et al, 2017). Our 
use of metabolite values scaled to creatine could also have meant that the results were 
caused by changes in voxel creatine levels. We overcame this limitation by also presenting 
water-scaled metabolite levels corrected for voxel tissue content, which were concordant 
with those scaled to creatine. Furthermore, while we recruited a representative sample of 
CHR-P males as typically found in specialist CHR-P services (Fusar-Poli et al, 2013b), none 
of which were taking antipsychotics, a number of participants were taking antidepressants 
and benzodiazepines. However, we found no material change in the results after exclusion 
of these cases, aside from an increase in thalamic choline after oxytocin. Future oxytocin 
studies should also investigate effects in females (which we excluded due to the known 
sexual dimorphism in oxytocinergic function (Rilling et al, 2014)) and may want to explore 
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variation in the oxytocin receptor gene, which is likely to modulate response to intranasal 
oxytocin (Tost et al, 2010). Finally, an interesting caveat is that while previous studies in 
autism spectrum disorder found no absolute differences in metabolite levels after acute 
oxytocin beyond choline in the ACC, oxytocin’s effects on medial prefrontal N-
acetylaspartate levels were related to the oxytocin-induced recovery in functional MRI signal 
in the same region during a social cognition fMRI task, and improvement in social-
communication related symptoms (Aoki et al, 2015). Examining whether changes in brain 
activation or functional connectivity after oxytocin are associated with oxytocin’s effects on 
metabolites in CHR-P patients remains an avenue for future research. 
 
Conclusions 
This study suggests that at ~75-93 minutes post-dosing, acute administration of oxytocin 
does not alter levels of glutamate, glutamate+glutamine, N-acetylaspartate, myo-inositol or 
choline in the hippocampus, ACC, or thalamus in those at CHR-P, aside from potential 
effects on choline in the ACC. 
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TABLES 
 
 
TABLE 1. Participant demographic and clinical characteristics 
 
 
aComprehensive Assessment of At-Risk Mental States (CAARMS) subgroup, BLIPS – Brief Limited 
Intermittent Psychotic Symptoms; APS – Attenuated Psychotic Symptoms; GRD – Genetic Risk and 
Deterioration. bSum of the global (severity) ratings for positive subscale items (P1-P4) of the CAARMS. 
cMean of pre-scan anxiety scores across conditions as measured by the State Trait Anxiety Inventory 
(STAI), with 4 subjects missing 1/20 items that constitute the total score, these were thus imputed using 
next-observation-carried-backwards. dReading the Mind in the Eyes (RMET) social cognition task - two 
subjects did not complete the RMET, leaving N=28. eCannabis use: 0 = never, 1 = experimental use (tried 
occasionally), 2 = occasional use (small quantities from time to time), 3 = moderate use (moderate 
quantities regularly / large amounts occasionally), 4 = severe use (frequently used large quantities, often 
to intoxication/debilitation). AUDIT – Alcohol Use Disorders Identification Test. CHR-P – Clinical High Risk 
for Psychosis.  
 
 
 Variable Total sample (N=30) 
Demographic Age, years; mean (SD) 23.2 (4.7) 
 Age range, years 18–35 
 Sex, male/female 30/0 
 Ethnicity (White/Black/Asian/Mixed) 16/6/4/4 
 Handedness, right/left 26/4 
 Education, years; mean (SD) 13.2 (1.9) 
Clinical CHR-P Subtypea (BLIPS/APS/GRD) 6/23/1 
 CAARMS attenuated positive symptomsb; 
mean (SD) 11.7 (3.3) 
 Baseline anxiety scorec; mean (SD) 35.6 (8.7) 
 GAF social score; mean (SD) 6.8 (1.5) 
 GAF role score; mean (SD) 7.0 (1.7) 
 RMET scored; mean (SD) 24.7 (5.6) 
 Current antidepressant medication (yes/no) 8/22 
 Current antipsychotic medication (yes/no) 0/30 
 Current benzodiazepine medication (yes/no) 1/29 
Substance Use Current smoker (yes/no) 17/13 
 Cigarettes/day; mean (SD) 9.8 (6.0) 
 Cannabis usee; median (range) 2 (0–4) 
 Alcohol, AUDIT total; mean (SD) 7.2 (7.7) 
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TABLE 2. Spectral and structural voxel data. Mean ± SD estimates of linewidths, signal-to-noise ratios, CRLB, and voxel proportions of white matter, 
grey matter and CSF in the hippocampus, anterior cingulate cortex and thalamus in oxytocin and placebo conditions. 
 
Spectral and structural voxel data 
 Hippocampus (N=26) Anterior Cingulate Cortex (N=28) Thalamus (N=28) 
 Oxytocin Placebo Statistic Oxytocin Placebo Statistic Oxytocin Placebo Statistic 
FWHM 0.07 ± 0.02 0.07 ± 0.03 t(25)=-1.12, p=.27 0.04 ± 0.01 0.04 ± 0.01 t(27)=-0.37, p=.71 0.05 ± 0.02 0.05 ± 0.01 t(27)=-0.63, p=.53 
SNR 15.54 ± 3.40 15.15 ± 2.59 t(25)=0.60, p=.56 36.07 ± 6.09 34.79 ± 5.72 t(27)=1.21, p=.24 21.0 ± 3.21 20.64 ± 2.83 t(27)=0.82, p=.42 
WM 0.36 ± 0.07 0.36 ± 0.09 t(25)=-0.25, p=.81 0.08 ± 0.02 0.09 ± 0.06 t(27)=-1.15, p=.26 0.78 ± 0.08 0.76 ± 0.08 t(27)=0.71, p=.48 
GM 0.60 ± 0.06 0.60 ± 0.07 t(25)=0.17, p=.87 0.65 ± 0.05 0.64 ± 0.08 t(27)=0.85, p=.40 0.22 ± 0.07 0.23 ± 0.08 t(27)=-0.80, p=.43 
CSF 0.04 ± 0.02 0.04 ± 0.02 t(25)=0.41, p=.69 0.27 ± 0.05 0.27 ± 0.06 t(27)=0.51, p=.62 0.005 ± 0.007 0.004 ± 0.005 t(27)=0.58, p=.57 
Cramér Rao Lower Bounds (CRLB) 
 Hippocampus (N=26) Anterior Cingulate Cortex (N=28) Thalamus (N=28) 
Metabolite Oxytocin Placebo Statistic Oxytocin Placebo Statistic Oxytocin Placebo Statistic 
Glu 9.62 ± 2.17 8.92 ± 1.62 t(25)=1.79, p=.09 5.04 ± 0.43 5.18 ± 0.43 t(27)=-1.07, p=.29 9.25 ± 2.27 9.21 ± 2.11 t(27)=0.06, p=.96 
Glx 10.65 ± 2.73 10.15 ± 2.22 t(25)=0.78, p=.44 5.54 ± 0.79 5.82 ± 0.61 t(27)=-1.49, p=.15 10.61 ± 2.47 11.18 ± 3.54 t(27)=-0.68, p=.50 
NAA 3.62 ± 0.98 3.88 ± 1.61 t(25)=-0.70, p=.49 2.21 ± 0.42 2.39 ± 0.50 t(27)=-1.72, p=.10 2.93 ± 0.90 2.93 ± 0.60 t(27)=0.00, p=1.00 
TCho 3.54 ± 0.76 3.65 ± 0.89 t(25)=-0.68, p=.50 2.71 ± 0.53 2.82 ± 0.61 t(27)=-0.83, p=.42 3.14 ± 0.45 3.25 ± 0.44 t(27)=-1.14, p=.26 
ml 5.04 ± 0.82 5.46 ± 1.61 t(25)=-1.49, p=.15 4.14 ± 0.76 4.11 ± 0.88 t(27)=0.19, p=.85 6.50 ± 1.43 7.29 ± 3.23 t(27)=-1.25, p=.22 
Cre 3.50 ± 0.65 3.73 ± 0.83 t(25)=-1.36, p=.18 2.07 ± 0.38 2.07 ± 0.26 t(27)=0.00, p=1.00 3.14 ± 0.45 3.18 ± 0.39 t(27)=-0.37, p=.71 
 
Abbreviations: FWHM, full width at half-maximum (linewidth) in ppm (parts per million); WM, white matter; GM, grey matter; CSF, cerebrospinal fluid; 
CRLB, Cramér Rao Lower Bounds; SNR, signal-to-noise ratio; Glu, Glutamate; Glx, Glutamate + Glutamine; NAA, N-acetylaspartate; TCho, Total 
Choline; ml, myo-Inositol; Cre, Creatine. 
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TABLE 3. Creatine-scaled and tissue-corrected metabolite values in the hippocampus, anterior cingulate cortex and thalamus (mean ± SD) 
 
Scaled to creatine 
 Hippocampus (N=26) Anterior Cingulate Cortex (N=28) Thalamus (N=28) 
Metabolite Oxytocin Placebo Statistic Oxytocin Placebo Statistic Oxytocin Placebo Statistic 
Glu/Cre 1.01 ± 0.16 1.07 ± 0.17 t(25)=-1.47, p=.15 1.33 ± 0.11 1.36 ± 0.16 t(27)=-0.74, p=.46 0.98 ± 0.18 0.98 ± 0.16 t(27)=-0.01, p=1.00a 
Glx/Cre 1.40 ± 0.24 1.42 ± 0.24 t(25)=-0.31, p=.76 1.70 ± 0.17 1.72 ± 0.23 t(27)=-0.45, p=.66a 1.19 ± 0.28 1.24 ± 0.27 t(27)=-0.54, p=.59 
NAA/Cre 1.24 ± 0.19 1.23 ± 0.16 t(25)=0.03, p=.98a 1.24 ± 0.09 1.24 ± 0.08 t(27)=-0.09, p=.93 1.59 ± 0.15 1.58 ± 0.19 t(27)=0.25, p=.81 
TCho/Cre 0.32 ± 0.03 0.33 ± 0.02 t(25)=-1.11, p=.28 0.25 ± 0.02 0.24 ± 0.02 t(27)=2.88, p=.008** 0.30 ± 0.03 0.29 ± 0.02 t(27)=1.63, p=.12 
mI/Cre 0.90 ± 0.12 0.86 ± 0.11 t(25)=1.35, p=.19a 0.74 ± 0.07 0.75 ± 0.06 t(27)=-0.82, p=.42a 0.58 ± 0.09 0.56 ± 0.11 t(27)=0.76, p=.45a 
Corrected for voxel tissue content 
 Hippocampus (N=26) Anterior Cingulate Cortex (N=28) Thalamus (N=28) 
Metabolite Oxytocin Placebo Statistic Oxytocin Placebo Statistic Oxytocin Placebo Statistic 
Glu 7.44 ± 1.33 7.66 ± 1.04 t(25)=-0.69, p=.50 15.43 ± 1.62 15.43 ± 1.74 t(27)=0.02, p=.99 7.30 ± 1.39 7.28 ± 1.12 t(27)=0.05, p=.96a 
Glx 10.37 ± 2.08 10.19 ± 1.81 t(25)=0.31, p=.76 19.65 ± 2.51 19.51 ± 2.53 t(27)=0.27, p=.79a 8.88 ± 2.06 9.16 ± 1.96 t(27)=-0.48, p=.64 
NAA 9.05 ± 0.90 8.80 ± 0.84 t(25)=1.18, p=.25a 14.33 ± 1.12 14.15 ± 1.23 t(27)=0.85, p=.40a 11.75 ± 0.87 11.62 ± 0.69 t(27)=0.76, p=.46 
TCho 2.38 ± 0.29 2.37 ± 0.41 t(25)=0.12, p=.90a 2.93 ± 0.36 2.77 ± 0.41 t(27)=2.57, p=.02* 2.19 ± 0.22 2.13 ± 0.20 t(27)=1.38, p=.18a 
ml 6.68 ± 1.28 6.21 ± 1.12 t(25)=1.57, p=.13 8.57 ± 1.11 8.57 ± 1.05 t(27)=-0.01, p=.99 4.29 ± 0.62 4.20 ± 0.93 t(27)=0.46, p=.65a 
Cre 7.42 ± 0.86 7.25 ± 1.13 t(25)=0.73, p=.47a 11.60 ± 1.05 11.42 ± 0.96 t(27)=1.15, p=.26a 7.44 ± 0.44 7.44 ± 0.72 t(27)=-0.05, p=.96 
 
Abbreviations: Glu, Glutamate; Glx, Glutamate + Glutamine; NAA, N-acetylaspartate; TCho, Total Choline; ml, myo-Inositol; /Cre, scaled to Creatine.   
aremoval of outliers made no material change to the results or conclusions 
*although significant at the p<.05 level, this does not meet the Bonferroni-corrected p<.01 threshold 
**significant at the Bonferroni-corrected p<.01 threshold 
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FIGURES 
 
FIGURE 1. Simplified schematic of proposed neural circuit mechanisms of glutamatergic 
dysfunction and CHR-P pathophysiology. In (1), low glutamate signal/input from 
hypofunctioning NMDARs (akin to ‘faulty homeostatic sensors’) leads GABAergic interneurons to 
homeostatically increase excitation by reducing inhibition (disinhibition) of glutamatergic pyramidal 
cells. However, by disinhibiting pyramidal cells (and thus increasing glutamate signalling) in this 
dysfunctional neural environment, the potential homeostatic adaptation becomes allostatic (2). In 
(3), enhanced excitation leads to an overdrive in the responsivity of midbrain dopamine neurons 
which project to the associative striatum (note that the connection between hippocampal pyramidal 
cells and midbrain dopamine neurons is presented as monosynaptic but is actually polysynaptic via 
the ventral striatum and ventral pallidum). Completing the (simplified) circuit, local glutamatergic 
tone is increased in (4) but is not detected as such by hypofunctioning NMDARs on GABAergic 
interneurons. Figure reproduced and adapted with permission from (Davies et al, 2019). For 
original diagrams and discussion of evidence for this proposed circuit, see (Krystal et al, 2017; 
Krystal and Anticevic, 2015; Lieberman et al, 2018; Lisman et al, 2008; Modinos et al, 2015). 
Abbreviations: Glu, glutamate; NMDAR, N-methyl-D-aspartate receptor; CA1, Cornu Ammonis 1. 
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FIGURE 2. Example 1H-MRS voxel positioning and spectra in (A) left hippocampus, (B) anterior 
cingulate cortex, and (C) left thalamus. 
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FIGURE 3. Choline levels (scaled to creatine) in the anterior cingulate cortex in oxytocin and 
placebo conditions. Individual data points are presented (overlaid) on standard boxplots, with grey 
lines connecting paired values.  
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Supplementary Experimental Procedures 
Subjects were asked to abstain from using recreational drugs for at least one week prior to 
each MRI scan, and alcohol for at least 24 hours prior to each MRI scan. Urine screening 
was conducted before the scan for each participant. 
 
The blinded spray bottles used for each session (containing oxytocin or matched placebo; 
see section below for formulation details) were visually identical and dispensed by the 
Maudsley Hospital Pharmacy. Intranasal administration followed recommended guidelines 
(Guastella et al, 2013) and a protocol adopted by a previous study conducted at our institute 
(Paloyelis et al, 2016). After a demonstration of the intranasal administration from a 
researcher using a spray bottle containing water, participants self-administered (in the 
presence of and with feedback from a researcher) one puff (4IU) of intranasal oxytocin or 
placebo every 30 seconds, alternating between nostrils, until 40IU (10 puffs) had been 
administered. The administration phase lasted approximately 4.5 minutes.  
 
Both the participants and researchers were blind to the (crossover) treatment sequence (AB 
or BA) allocation. A randomisation list was generated by the Maudsley Hospital Pharmacy, 
which determined whether a participant received oxytocin or placebo in their first study visit 
and vice versa for the second study visit. On recruitment of a study participant, an unblinded 
clinical trial pharmacist, who was not involved with the rest of the study, allocated the 
participant to one of the two sequences (AB, BA) based on the randomisation list. Allocation 
information was kept concealed in the Maudsley Hospital Pharmacy. 
 
Oxytocin and Placebo Formulation 
The finished intranasal product was manufactured by the Pharmacy Manufacturing Unit, 
Guy’s and St Thomas’ NHS Foundation Trust. Active (Oxytocin): Syntocinon was obtained 
as Syntocinon Spray, marketed by Hersteller, 68330 Huningue, France. This was decanted 
into a 10ml amber dropper bottle and capped with a 10IU white nasal atomiser with 69mm 
dip and overcap. Placebo was placed in the same containers as above and contained 
excipients matching the active formulation. 
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Exploratory correlations 
 
Social Cognition 
 
Table S1. Spearman’s correlation coefficients for change in metabolites (oxytocin – placebo) 
in the hippocampus, ACC and thalamus vs RMET scores 
** Correlation is significant at the 0.01 level (2-tailed). 
Metabolite Spearman’s Rho for RMET Sig. (2-tailed) N 
Hippocampus 
Change in Glu/Cre -.546** .005 25 
Change in Glx/Cre -.509** .009 25 
ACC 
Change in Glu/Cre .288 .145 27 
Change in Glx/Cre -.035 .861 27 
Thalamus 
Change in Glu/Cre .120 .551 27 
Change in Glx/Cre .232 .245 27 
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Figure S1. Scatterplots depicting relationship between change in glutamate and Glx 
scaled to creatine (oxytocin – placebo) in the hippocampus vs RMET scores 
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Attenuated Psychotic Symptoms 
 
Table S2. Spearman’s correlation coefficients for change in metabolites (oxytocin – placebo) 
in the hippocampus, ACC and thalamus vs CAARMS positive subscale severity scores 
 
There were no significant correlations between CAARMS positive scores and change in 
glutamate or Glx scaled to creatine in the hippocampus, ACC or thalamus (Table S2). 
However, after removing those subjects taking antidepressants and benzodiazepines in 
sensitivity analyses, there was a significant positive association between CAARMS positive 
scores and change in thalamic glutamate scaled to creatine (rho= .523, p=.018; N=20) and 
change in thalamic Glx scaled to creatine (rho= .606, p=.005; N=20)(Figure S2). That is, 
higher levels of positive symptoms were associated with increased glutamate (and Glx) after 
oxytocin, while lower levels of positive symptoms were associated with a reduction of 
thalamic glutamate (and Glx) after oxytocin vs placebo (Figure S2). 
Metabolite Spearman’s Rho for CAARMS Sig. (2-tailed) N 
Hippocampus 
Change in Glu/Cre -.326 .111 25 
Change in Glx/Cre -.211 .311 25 
ACC 
Change in Glu/Cre .043 .831 27 
Change in Glx/Cre .175 .383 27 
Thalamus 
Change in Glu/Cre .344 .079 27 
Change in Glx/Cre .336 .087 27 
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Figure S2. Scatterplots depicting relationship between change in glutamate and Glx 
scaled to creatine (oxytocin – placebo) in the thalamus vs CAARMS positive subscale 
severity scores [after excluding those subjects taking antidepressants or 
benzodiazepines in sensitivity analyses] 
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Updated Power Calculations 
Updated power calculations were computed using the mean and SD of control metabolite 
values from a previous study (Stone et al, 2009). All calculations are for paired t-tests (two-
tailed; 80% power; a=.05), where the assumed SD is the same for both sessions: SDdiff = √2 
x SD. The final sample sizes in the current study were hippocampus=26, ACC=28, 
thalamus=28.  
 
Overall, the updated power calculations indicated that the minimum effect size (Cohen’s D) 
for within-subject change in glutamate (detectable at 80% power when a=.05), was d=0.57 
(~18% change in glutamate levels) in the hippocampus, d=0.55 (~13% change) in the ACC, 
and d=0.55 (~13% change) in the thalamus. The same values for Glx were: d=0.57 (~20% 
change in Glx) in the hippocampus, d=0.55 (~14.5% change) in the ACC, and d=0.55 (~19% 
change) in the thalamus. Therefore, it is possible that oxytocin induced changes of smaller 
magnitude but we were unable to detect them with our final sample sizes due to low 
statistical power. Detailed power calculations are presented in Table S3 below. 
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Table S3. For each Cohen’s D effect size (small, medium, large), showing the 
associated % change in metabolite, the power we had in the current study to detect 
this % change (or D) [given the sample size for each region], and the required sample 
size to detect such an effect size 
 
 
 
 
 
Cohen’s D 
Glutamate Glx 
% change 
in 
metabolite 
Power in 
this 
study to 
detect D 
Required 
N 
% change 
in 
metabolite 
Power in 
this 
study to 
detect D 
Required 
N 
Hippocampus (this study N=26) 
Small (d=0.2) 7 18% 176 7 16% 210 
Medium (d=0.5) 16 66% 36 18 69% 34 
Large (d=0.8) 26 97% 15 29 98% 15 
ACC (this study N=28) 
Small (d=0.2) 5 19% 180 5 16% 223 
Medium (d=0.5) 12 73% 33 13 71% 35 
Large (d=0.8) 19 98% 15 21 98% 15 
Thalamus (this study N=28) 
Small (d=0.2) 5 18% 186 7 18% 195 
Medium (d=0.5) 12 72% 34 17 71% 35 
Large (d=0.8) 19 98% 15 28 98% 15 
 
 
From Table S3 it becomes clear that effects of oxytocin would have to be of medium to large 
magnitude (as defined by Cohen’s D) for us to detect them with our final sample sizes. 
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